Clinical application of BVS5000 left ventricular assist device in heart failure patients

• Published in: Chinese medical journal 2008-05, Vol.121 (10), p.877-880
• Main Authors: Luo, Xin-jin, Hu, Sheng-shou, Sun, Han-song, Xu, Jian-ping, Liu, Ping, Zheng, Zhe, Ma, Wei-guo, Zhang, Yan
• Format: Article
• Language: English
• Subjects: Adult; Aged; Coronary Artery Bypass; Device Removal; Heart Failure - surgery; Heart-Assist Devices; Humans; Male; Middle Aged; Prosthesis Implantation; Shock, Cardiogenic - surgery; Treatment Outcome; 临床应用; 左心室支撑装置; 心力衰竭; 手术治疗
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/00029330-200805020-00003

Background Mechanical ventricular assistance is an important therapeutic method for severe heart failure patients. A variety of ventricular assist devices have been designed for use, The purpose of this report was to describe the experience of using Abiomed BVS5000 as a means of left ventricular support as a clinical treatment for heart failure patients. Methods From February 2004 to April 2006, 12 male patients were supported with Abiomed BVS5000 left ventricular assist device （LVAD） at Fu Wai Hospital. The average age was （55.2±9.6） years （range 39 to 68 years）. The mean body surface area was （1.76±0.1） m^2 （range 1.6 to 1.9 m^2 ）. Devices were inserted for post-cardiotomy shock after coronary artery bypass graft in 11 patients （92%） and in 1 dilated cardiomyopathy patient for acute cardiogenic shock. Modified cannulation methods by inserting the arterial cannulae in femoral artery and inserting the venous cannula in left atrium through a segment of bovine jugular vein were used in 7 patients. In this way, the device could be taken off without re-sternotomy when support was finished. A comparison was made between the modified method and routine left atrium-to-ascending aorta cannulating method. Results The median duration of support was 5 （3-43） days, with support flow rate of 3.8-4.5 L/min. There were 9 （75%） patients weaned from support and 8 （67%） patients discharged from the hospital. Four （33%） patients were dead. The most common morbidity was adverse neurological events. There is no statistical difference between modified and routine method on average in BVS5000 support duration, in assisted flow rate, in mechanical ventilation duration, in the intensive care unit stay and thoracic drainage. Conclusions The Abiomed BVS5000 is valuable to support patients with acute cardiogenic shock for short-term use. By the modified cannulating method, the weaning procedure can be effectively simplified. Optimization of inserting indication remains challenging and attributes to a successful assist program.